Association between KISS1 rs5780218 promoter polymorphism and onset of growth hormone secreting pituitary adenoma
Carregando...
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
MASSON EDITEUR
Citação
ANNALES D ENDOCRINOLOGIE, v.80, n.2, p.96-100, 2019
Resumo
Objectives. - This study analyzed the KISS1 c.-145delA (rs5780218) promoter polymorphism in a cohort of patients with growth hormone secreting pituitary adenoma (somatotropinoma) and controls, to investigate its role in the incidence of acromegaly and to assess patient/tumor characteristics. Material and methods rs5780218 allelic and genotypic distributions were compared between 49 somatotropinoma patients and 167 healthy controls. rs5780218 was also assessed in relation to patient characteristics and tumor aggressiveness, as characterized by tumor invasion and resistance to conventional therapy. The relationship between KISS1 mRNA expression and the rs5780218 genotype was also assessed in available pituitary tumor samples. Results. - The homozygous -/- variant genotype was associated with high rates of somatotropinoma (P < 0.01), but not with tumor invasiveness, patient characteristics or hormonal remission. KISS1 mRNA expression was much lower in somatotropinomas carrying the deleted allele than in homozygous wild type AA. Conclusions. - In this pilot study, the rs5780218 promoter polymorphism was evaluated in pituitary adenoma, and showed a possible association with the incidence of somatotropinoma but not with tumor progression.
Palavras-chave
KISS1, Rs5780218 promoter SNP, MRNA expression, Somatotropinomas
Referências
- Abreu A, 2016, PITUITARY, V19, P448, DOI 10.1007/s11102-016-0725-2
- An XP, 2015, ANIM REPROD SCI, V155, P36, DOI 10.1016/j.anireprosci.2015.01.013
- Beck BH, 2010, EUR J CANCER, V46, P1283, DOI 10.1016/j.ejca.2010.02.023
- Chatzellis E, 2015, NEUROENDOCRINOLOGY, V101, P87, DOI 10.1159/000371806
- Quevedo EGC, 2015, DIS MARKERS, DOI 10.1155/2015/365845
- Deng N, 2017, ONCOTARGET, V8, P110635, DOI 10.18632/oncotarget.22372
- Di Ieva A, 2014, NAT REV ENDOCRINOL, V10, P423, DOI 10.1038/nrendo.2014.64
- Foltran RK, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431X20187427, 10.1590/1414-431x20187427]
- Gadelha MR, 2017, PITUITARY, V20, P10, DOI 10.1007/s11102-017-0789-7
- Gahete MD, 2016, MOL CELL ENDOCRINOL, V438, P100, DOI 10.1016/j.mce.2016.07.039
- KNOSP E, 1993, NEUROSURGERY, V33, P610, DOI 10.1227/00006123-199310000-00008
- Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
- Melmed S, 2011, NAT REV ENDOCRINOL, V7, P257, DOI 10.1038/nrendo.2011.40
- Pinilla L, 2012, PHYSIOL REV, V92, P1235, DOI 10.1152/physrev.00037.2010
- Silveira LG, 2013, ADV EXP MED BIOL, V784, P187, DOI 10.1007/978-1-4614-6199-9_9
- Yaron M, 2015, PITUITARY, V18, P306, DOI 10.1007/s11102-014-0572-y
- 1993, NEUROSURGERY, V33, P610
- 2011, EUR J ENDOCRINOL, V164, P355, DOI 10.1530/EJE-10-0905